Notably, patients with immune-inflamed melanomas generally exhibit greater overall survival (OS) and PFS when receiving anti-PD-1 or anti-CTLA-4 immunotherapy than those with melanomas categorized into the immune-desert type [44]. Here, CTLA4 is linked to melanoma.